Caribou Biosciences (CRBU) shares were down 39% in premarket activity Wednesday after the company overnight said that it was exploring strategic alternatives to maximize stockholder value and that it planned to discontinue development activities for its two allogeneic CAR-T cell therapy programs.

OLB Group (OLB) stock was 31% lower pre-bell, reversing a nearly 118% gain in the previous session.

Actuate Therapeutics (ACTU) shares were down 19% after the company filed a preliminary prospectus with the US Securities and Exchange Commission for a proposed offering of 50 million common shares.

Delixy (DLXY) stock was 15% lower in premarket activity, reversing a 22% gain from Tuesday's session.

QTREX Quantum (QTEX) shares were down 13%, after closing the previous session with a 3.3% rise.